[Clinical study on stage XXXX and grade 3 transitional cell @entity150 ].

@entity1 @entity2558 @entity150
Thirty-three @entity1 who had transitional cell @entity150 with stage @entity2558 and grade 3 components were treated between January 1980 and December 1992. Clinical study was done for these 33 @entity1 on treatment modalities and it's problem, intravesical recurrence, disease progression and prognosis. Twenty-five of 33 @entity1 underwent bladder-sparing surgeries and total cystectomy was performed for another 8 @entity1 as initial treatment. Intravesical recurrence was observed in 18 (72%) of 25 @entity1 who underwent initial bladder-sparing surgeries. Recurrence-free rate was 44% for 1 year and mean period to recurrence from initial therapy was 13.1 months. Although some adjuvant therapy after initial treatment was performed for 20 @entity1 , it's efficacy in preventing intravesical recurrence could not be confirmed. Disease progression was recognized in 10 (40%) of 25 @entity1 initially treated by bladder-sparing surgeries after median latent period of 33.7 months, whereas only one (12.5%) of another 8 @entity1 who underwent total cystectomy showed progression, and 5-year progression-free rate after initial bladder-sparing surgeries was 55.6%. Three and five-year actural survival rate in all cases were 81.5% and 65.1%, respectively. According to initial treatment, 5-year survival rate was 62.2% for the @entity1 treated by bladder-sparing surgeries, whereas it was 83.3% for the cases who underwent total cystectomy. However statistical significant difference was not recognized. In view of disease progression after initial bladder-sparing surgeries, @entity1 with progression yealed a 45.7% 5-year survival rate compared to 81.5% for the @entity1 without progression, and significant difference was demonstrated between them.(ABSTRACT TRUNCATED AT 250 WORDS)
